Compare Amgen, Inc. (AMGN) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs VNET Group Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while VNET Group Inc trades at $7.8 (market cap $2.28B). The key difference: Amgen, Inc. is far larger — about 86× VNET Group Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| AMGN | VNET | |
|---|---|---|
Market Cap | $196.12B | $2.28B |
Sector | Health | Technology |
52-Week High | $388.16 | $14.03 |
52-Week Low | $271.18 | $7.34 |
Enterprise Value | $241.41B | $5.41B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VNET trades at $8.01, down 0.5% with bearish technical signals. The company reported Q1 2026 revenue growth driven by AI demand but posted a significant net loss of $1.20 per share, missing estimates. Analyst sentiment remains positive with 62.5% buy ratings and a 54% upside target. Recent strategic investments and leadership changes signal transformation amid ongoing profitability challenges.
The outlook balances strong AI-driven revenue potential against persistent profitability concerns. Investment opportunity lies in market share gains from AI infrastructure demand, while risks include negative margins, class action litigation, and execution challenges during leadership transition. The stock faces near-term pressure from consecutive earnings misses despite long-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
